EmblemHealth conceded US sham litigation claims fail, Alexion says
EmblemHealth has conceded it cannot establish antitrust standing to pursue its remaining claims over alleged sham litigation as part of its antitrust suit over Soliris, Alexion Pharmaceuticals said in a motion...To view the full article, register now.
Already a subscriber? Click here to view full article